What is Senti Biosciences's market cap?

Senti Biosciences (SNTI) has a market capitalization of $11.6M and trades on NASDAQ.

Who are Senti Biosciences's competitors?

Senti Biosciences's key competitors include CRISPR Therapeutics AG, Gilead Sciences, Inc., Nkarta, Inc., and others. These companies compete in similar markets and product categories.

Who does Senti Biosciences partner with?

Senti Biosciences's notable partners include BlueRock Therapeutics, Bayer AG, Spark Therapeutics, and others.

What subsidiaries does Senti Biosciences have?

Senti Biosciences's subsidiaries include Senti Sub I, Inc..

Where is Senti Biosciences headquartered?

Senti Biosciences is headquartered in United States of America and employs approximately 48 people. It has been publicly traded since 2022.

Senti Biosciences

SNTI

Senti Biosciences is a clinical-stage biotechnology company specializing in the development of next-generation cell and gene therapies using a proprietary synthetic biology platform.

Market cap

$11.64M-75.2%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$16.0K EPS-$0.36Miss by $0.09

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$14.9K

EPS estimate-$0.33

Competitors

By market cap

Gilead Sciences$162.05B+15.3%

Bristol-Myers Squibb$127.75B+32.1%

CRISPR Therapeutics$4.6B-16.4%

Beam Therapeutics$2.6B+23.1%

Immix Biopharma, Inc.$618.6M+716%

Fate Therapeutics$283.2M+90.1%

Nkarta, Inc.$161.7M+3.6%

Senti Biosciences$11.6M-76.1%

By revenue growth

Beam Therapeutics+158%

Gilead Sciences+3.5%

Bristol-Myers Squibb+1.8%

CRISPR Therapeutics-89.1%

By net margin

Gilead Sciences30.99%+10.2pp

Bristol-Myers Squibb15.01%+3.8pp

Beam Therapeutics-742.72%+338pp

CRISPR Therapeutics-13,856.54%-12,833pp

Profile

Senti Biosciences is a clinical-stage biotechnology company specializing in the development of next-generation cell and gene therapies using a proprietary synthetic biology platform. The company engineers gene circuits designed to reprogram cells with biological logic, allowing therapies to sense, compute, and respond to specific cellular environments. Its primary focus is on creating off-the-shelf CAR-NK cell therapies that precisely target cancer cells while sparing healthy tissue.

Competitive position

A leader in synthetic biology-based gene circuit engineering for cell therapies, holding a significant patent portfolio in logic-gated CAR-NK technologies.

GeographiesUnited States, Australia, China

Customer segmentsPharmaceutical Companies, Clinical Trial Sites

Business modelR&D, Licensing, Collaboration

SuppliersHealthy adult donor leukopaks, Viral vector manufacturers, Laboratory equipment suppliers, Academic licensing partners

CustomersClinical trial participants, Strategic biopharma partners, Specialized healthcare providers

CountryUnited States of America

Listed2022

Employees48.0

CEOTimothy K. Lu

SectorHealthcare

IndustryBiotechnology

Websitesentibio.com

FilingsSEC EDGAR

Questions, answered.

What is Senti Biosciences's market cap?: Senti Biosciences (SNTI) has a market capitalization of $11.6M and trades on NASDAQ.
Who are Senti Biosciences's competitors?: Senti Biosciences's key competitors include CRISPR Therapeutics AG, Gilead Sciences, Inc., Nkarta, Inc., and others. These companies compete in similar markets and product categories.
Who does Senti Biosciences partner with?: Senti Biosciences's notable partners include BlueRock Therapeutics, Bayer AG, Spark Therapeutics, and others.
What subsidiaries does Senti Biosciences have?: Senti Biosciences's subsidiaries include Senti Sub I, Inc..
Where is Senti Biosciences headquartered?: Senti Biosciences is headquartered in United States of America and employs approximately 48 people. It has been publicly traded since 2022.